نتایج جستجو برای: polycythemia vera
تعداد نتایج: 10734 فیلتر نتایج به سال:
By BARUCH MODAN I HE USE of pa2 in the therapy of polycythemia vera has continued to be a controversial subject since it was first introduced.15”5 Although considered as the ultimate treatment for polycythemia vera by many hematologists it has, on the other hand, been discredited by others as being responsible for a high proportion of deaths from acute leukemia. The main obstacle to an objectiv...
The authors describe a 19 year old male with an isolated but absolute erythrocytosis with iron deficiency without evidence for polycythemia vera as well as another causes of erythrocytosis. The polycythemia was due to a recently described von Hippel-Lindau (VHL) mutation. By stopping iron therapy there was no more requirements for phlebotomy in this patient.
By BARUCH MODAN I HE USE of pa2 in the therapy of polycythemia vera has continued to be a controversial subject since it was first introduced.15”5 Although considered as the ultimate treatment for polycythemia vera by many hematologists it has, on the other hand, been discredited by others as being responsible for a high proportion of deaths from acute leukemia. The main obstacle to an objectiv...
nicious anemia and polycythemia, or of pernicious anemia and acute myeloblastic leukemia, is extremely rare. Wintrobe’ notes only four instances imi which pernicious anemia preceded the onset of acute myeloblastic leukemia. Polycythemia following pernicious anemia is of equal rarity.’ ‘ 2 On the other hand, the emergence of acute leukemia in cases of polycythemia, while uncomiimon, is miot as r...
Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by abnormal growth of erythroid precursors in the bone marrow. Almost all patients with PV, around 97%, have a mutation in Janus kinase 2 (JAK2). It is through the activation of JAK/Signal Transducers and Activators of Transcription (STAT) protein signaling pathway that the JAK2 mutation is thought to induce cellular ...
I N A RECENT REVIEW of the clinical and epidemiologic aspects of polycythemia, Modan’ discussed familial polycythemia, which was first reported in 19072 and in several reviews subsequently.3 5 As more sophisticated diagnostic technics have become available, familial polycythemia has been recognized to be a clinical entity, distinct from polycythemia rubra vera (PRV) in its clinical, hematologic...
INTRODUCTION The World Health Organization classification of chronic myeloproliferative disease encompasses eight entities of bone marrow neoplasms, among them Breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1-positive chronic myeloid leukemia and polycythemia vera. Polycythemia vera requires, in the majority of cases (95%), the negativity of Breakpoint cluster region-A...
The clinical course of polycythemia vera and essential thrombocythemia is potentially associated with long-term severe complications, such as evolution to myelofibrosis or acute myeloid leukemia. Allogeneic stem cell transplantation is currently the only potentially curative treatment for advanced polycythemia vera or essential thrombocythemia. We analyzed 250 consecutive patients with an initi...
A rare clinical observation of advanced myeloid sarcoma developed through blast transformation post-polycythemia vera myelofibrosis as extramedullary manifestation acute leukemia affecting larynx, laryngopharynx, trachea, soft tissues the neck, pleura, and skeletal bones is presented.
BACKGROUND The V617F mutation, which causes the substitution of phenylalanine for valine at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. However, the molecular basis of these myeloproliferative disorders in patients without the V617F mutation is unclear. METHODS We searched f...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید